Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Nov 17;105(12):1850–1855. doi: 10.1038/bjc.2011.493

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

¹¹C-erlotinib PET/CT demonstrates the heterogeneous nature of advanced lung cancer. Two transaxial slices of (left) contrast-enhanced CT; (middle) ¹⁸F-FDG PET/low-dose CT, and (right) ¹¹C-erlotinib PET/low-dose CT. A 48-year-old patient (no. 7) with NSCLC in the right lung and enlarged mediastinal lymph nodes (upper and lower panel left figure, arrows). Both ¹⁸F-FDG and ¹¹C-erlotinib accumulated in lymph nodes at positions 4R and 5 (upper panel, arrows). The tumour in the right lung and one of the lymph nodes at position 7 showed only a weak accumulation of ¹¹C-erlotinib (arrows). The ratio between the ¹¹C-erlotinib average radioactivity concentrations in the lymph node metastasis and that in surrounding lung tissue was 2 (see Figure 4).